Timely target turnover

Companies don't get much money these days either for technology or for preclinical compounds. As a result, many former technology platform companies have jumped into the costly adventure of developing products through Phase II proof of principle.

German chemogenomics play Graffinity Pharmaceuticals AG (Heidelberg, Germany) does not want to follow that path. Instead, it plans to make a business from preclinical compounds as it thinks it can process more targets in less time and at less cost than other companies...